TL;DR
This study reveals that the oncoprotein CREPT acts as a crucial co-factor for MYC, a key driver of many cancers. CREPT directly interacts with MYC to enhance the transcription of MYC-driven oncogenes, thereby promoting cell transformation and tumor growth. Targeting the CREPT-MYC interaction could offer a novel therapeutic strategy for MYC-driven cancers.
What Problem Does This Paper Address?
The MYC proto-oncogene family is implicated in over 70% of human cancers, making MYC a central player in oncogenesis. Despite its significance, directly targeting MYC for therapeutic intervention has proven challenging, leading researchers to explore its complex regulatory networks and co-factors. While MYC's role in driving cell proliferation, differentiation, and metabolism is well-established, the precise molecular mechanisms by which it orchestrates these processes, particularly its interactions with other proteins to initiate transcription, remain incompletely understood. This paper addresses this gap by investigating the role of CREPT, an oncoprotein frequently overexpressed in various cancers, as a potential co-factor in MYC-driven transformation and tumor progression.
Methods
The researchers employed a multi-pronged approach to dissect the CREPT-MYC interaction and its functional consequences:
- Conditional Gene Deletion: They generated MYC-transformed mouse embryonic fibroblasts (MEFs) with a conditional knockout of CREPT using a Cre-lox system. This allowed them to study the effects of CREPT loss on MYC-driven transformation.
- Cellular Assays: Standard assays like colony formation, soft agar assays, and cell proliferation assays were used to assess the impact of CREPT deletion and re-expression on cellular transformation and growth.
- Cell Cycle Analysis: Flow cytometry was used to analyze cell cycle progression (G1/S and G2/M phases) after synchronizing cells, revealing delays in CREPT-deficient cells.
- Molecular Interaction Studies:
- Co-immunoprecipitation (Co-IP): This technique was used to demonstrate the physical interaction between CREPT and MYC, both endogenously and exogenously expressed.
- GST Pull-down Assays: These assays confirmed a direct binding interaction between CREPT and MYC in vitro.
- Mutagenesis Studies: Specific domains and residues within CREPT and MYC were mutated to identify critical regions for their interaction.
- Transcriptional Analysis:
- RNA-sequencing (RNA-seq): This was performed to profile global gene expression changes in CREPT-deficient vs. wild-type MYC-transformed MEFs, identifying differentially expressed genes (DEGs).
- Gene Set Enrichment Analysis (GSEA): GSEA was used to determine if the DEGs were enriched in known MYC target gene sets.
- Quantitative RT-PCR (qRT-PCR): This was used to validate the RNA-seq findings and assess the expression of specific MYC target genes.
- Chromatin Immunoprecipitation (ChIP) Assays: ChIP was employed to investigate the recruitment of RNA Polymerase II (RNAPII) to MYC-binding promoters in the presence or absence of CREPT.
- Xenograft Models: Tumor formation and growth were assessed in nude mice injected with human cancer cells overexpressing CREPT or its mutants, providing in vivo validation of CREPT's role in tumorigenesis.
- Bioinformatics Analysis: Publicly available datasets (TCGA) were analyzed to assess the correlation between CREPT and MYC expression in human cancers.
Datasets
- The Cancer Genome Atlas (TCGA): Used to analyze the correlation between CREPT and MYC expression in various human tumors.
- Cistrome database: Utilized to examine the occupancy of RNAPII and MYC at the promoters of MYC target genes.
Key Insights and Ideas
- CREPT as a Direct MYC Co-factor: The study provides compelling evidence that CREPT is not just correlated with MYC activity but directly interacts with MYC to enhance its transcriptional function. This moves beyond correlative observations to a mechanistic understanding.
- The PEST Domain of MYC is Crucial: The identification of the PEST domain in MYC, specifically residues 211-231, as the key interaction site for CREPT is a significant finding. This domain is known for its role in protein degradation, suggesting CREPT might also influence MYC stability or localization in a way that promotes transcription.
- Arginine 34 in CREPT is Essential: Pinpointing Arginine 34 (R34) in CREPT's CID domain as critical for MYC binding and subsequent transformation highlights a specific molecular target for therapeutic intervention. Mutating this residue abolishes CREPT's ability to promote MYC-driven tumorigenesis.
- CREPT Bridges MYC and RNAPII: The research demonstrates that CREPT acts as a molecular bridge, facilitating the interaction between the MYC-MAX complex and RNAPII. This is crucial for the efficient recruitment of RNAPII to MYC target gene promoters, thereby driving transcription.
- Cell Cycle Regulation is Tied to CREPT-MYC Interaction: The observed delays in the S and G2/M phases in CREPT-deficient cells suggest that the CREPT-MYC interaction is particularly important during these critical stages of the cell cycle, aligning with MYC's known role in cell division.
- CREPT-MYC Interaction is a Driver of Colorectal Cancer: The strong correlation between CREPT and MYC expression in colorectal cancer, coupled with in vivo xenograft data showing that CREPT-R34A mutants fail to promote tumor growth, strongly implicates this interaction in the progression of this specific cancer type.
Key Results
- CREPT deletion impairs MYC-induced transformation: Loss of CREPT significantly reduced colony formation and cell proliferation in MYC-transformed MEFs.
- CREPT overexpression enhances MYC-driven transformation: While CREPT alone wasn't sufficient to induce transformation, its overexpression amplified MYC-induced colony formation.
- CREPT deficiency delays cell cycle progression: CREPT-deficient cells showed delays in the S and G2/M phases.
- CREPT directly interacts with MYC: Co-IP and GST pull-down assays confirmed a direct physical interaction between CREPT and MYC.
- Specific domains are critical for interaction: The PEST domain of MYC and Arginine 34 of CREPT were identified as essential for their binding.
- CREPT facilitates RNAPII recruitment: ChIP assays showed that CREPT promotes RNAPII occupancy at MYC target gene promoters.
- CREPT and MYC are co-expressed in human cancers: A strong positive correlation was observed in colon cancer and other malignancies.
- CREPT-MYC interaction promotes tumor growth in vivo: Xenograft models demonstrated that CREPT overexpression enhances tumor growth, while the R34A mutant failed to do so.
Limitations and Future Work
- Cell Cycle Specificity: While the study observed that the CREPT-MYC interaction peaks in the G2/M phase, the precise mechanisms governing this cell cycle-dependent binding are not fully elucidated. Future work could explore how post-translational modifications of MYC or CREPT influence their interaction during specific cell cycle stages.
- Aurora B Kinase Role: The paper mentions that Aurora B phosphorylates CREPT and regulates malignant features of tumors. Investigating whether Aurora B directly regulates the CREPT-MYC interaction is suggested as a future direction.
- Co-regulation of CREPT and MYC: The study notes that CREPT and MYC are co-expressed in several cancers, and while CREPT might regulate MYC expression, the reverse regulation (MYC regulating CREPT) is also proposed. Further research is needed to fully understand how these two genes are coordinately regulated during tumorigenesis.
- Therapeutic Potential: The findings strongly suggest that targeting the CREPT-MYC interaction is a promising therapeutic avenue. Future work would involve developing and testing specific inhibitors of this interaction in preclinical and clinical settings.
Summary updated